Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1643 1652
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18565831 | METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS | Non-Final OA | Regents of the University of Minnesota |
| 17904473 | CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 17611019 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18202066 | MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME | Non-Final OA | The Johns Hopkins University |
| 18308778 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 | Non-Final OA | SANOFI |
| 18300169 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18039071 | EXOSOMES EXPRESSING RSVF AND USE THEREOF | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18033777 | ENGINEERED NK CELLS | Non-Final OA | City of Hope |
| 18420883 | COMBINATIONS FOR TREATING CANCER | Non-Final OA | Purdue Pharma L.P. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy